Last updated : April 17, 2026 10:23 am
The investment case for health technology in India is frequently overstated in one direction and understated in another
The infrastructure-first thesis served its era. The next cycle of alpha in Indian healthcare will be won by funds that can distinguish a high-occupancy hospital from a high-performing one — and back the latter at scale.
For two decades, the dominant playbook in Indian healthcare private equity ran on a simple premise: build more beds in growing cities, and patient volume will follow. The logic was defensible when supply was genuinely scarce and when differentiation between facilities was opaque to payers and patients alike. Both conditions are now eroding.
The signal that an institution is busy and the signal that it is delivering value have always been different signals. Fee-for-service structures, designed to reward throughput, made it rational to conflate the two. High bed occupancy, strong OPD footfall, and growing procedure volumes looked like performance indicators — and in a capital-light market, they functioned as proxies. They are no longer sufficient. A full ward is a billing event. A patient who does not return is the outcome.
Clinical governance that sits below financial management is a governance failure. It also turns out to be a value destruction event on a five-to-ten-year hold.
What Value-Based Investing Actually Measures
The phrase "value-based care" has become ubiquitous enough to be nearly meaningless. In due diligence terms, what it demands is specific: can this institution measure the cost of a clinical episode end-to-end, and can it demonstrate that its outcomes on that episode — complication rates, readmission windows, functional recovery — are defensible at the price it charges? Most Indian hospitals cannot answer this question with data. The ones that can are structurally mispriced.
Investors operating with this lens are asking a different set of entry questions. What is the diagnostic accuracy rate, and how does it trend? What are the post-surgical complication rates by procedure, and how do they compare across comparable facilities? Is there a clinical pathway governance structure, or does treatment protocol vary by attending physician? These are not abstract quality metrics — they are the variables that drive referral loyalty, clinical talent retention, and regulatory durability. A hospital that performs well on these dimensions does not need to buy patient volume. It compounds it.
Technology as a Leverage Mechanism, Not a Disruption Narrative
The investment case for health technology in India is frequently overstated in one direction and understated in another. The disruption narrative — AI replacing clinicians, telemedicine collapsing geography — misses how constrained the demand side remains. The leverage narrative, which is less dramatic and more accurate, is this: India has a structural specialist shortage that no medical college pipeline will resolve in the next decade. Technology's role is not to create new care models from scratch; it is to extend the productive frontier of the clinicians who exist.
AI-assisted radiology does not replace a trained radiologist — it allows one radiologist to read more, and with measurably better pattern recognition on high-acuity presentations. Remote monitoring protocols allow a cardiologist to manage post-discharge patients at scale without requiring physical attendance for every follow-up. The return on these investments is not the platform valuation — it is the unit economics of the underlying clinical operation. Platforms that can demonstrate measurable specialist leverage ratios, tracked rigorously over time, are building a moat that infrastructure alone never could.
The Tier-2 Structural Thesis Is Not a Thematic Bet — It Is a Supply Gap
The framing of Tier-2 and Tier-3 healthcare as a social impact play has obscured the economic logic. This is, at its core, an asset-liability mismatch. Bed density in non-metro India sits at <1.2 per 1,000 against 2.7–3.0 in major urban centres. That gap represents suppressed demand that is now finding expression — through rising insurance penetration, improved clinical awareness, and a growing cohort of specialists who are building outside metro markets by choice rather than necessity.
The investment implication is not simply that Tier-2 assets are cheaper to acquire. It is that the demand-supply dynamic in these markets structurally supports stronger yield on incremental clinical capacity than a comparable asset in a saturated metro. Platform clustering in secondary geographies — anchoring a clinical hub and building spoke infrastructure around it — creates competitive moats that operate differently from urban consolidation. The referral network becomes captive. The clinical talent, once embedded, is retained. The regulatory overhang from urban competitors is absent. This is consolidation with structural tailwinds, not against them.
The Governance Premium
Healthcare is one of the few asset classes where governance quality is directly legible in clinical outcomes data — if you know which data to read. Institutions with genuine clinical governance structures, where treatment protocols are reviewed, complication events are reported and analysed, and billing practices are subject to internal audit, produce measurably different outcome profiles from those that are managed primarily as revenue-generation vehicles. That difference is not priced into most entry multiples. It should be.
India's structural advantage here is genuine. Systems in the West carry decades of entrenched fee-for-service incentives, politically difficult to unwind and economically embedded in every layer of the care delivery chain. Indian healthcare, still in active formation, retains the optionality to build outcome-driven, ethically-governed clinical platforms from the ground up — with digital infrastructure as a native layer rather than a retrofit.
The funds that understand this, and are willing to hold through the duration required to demonstrate it, are not making a thematic bet on a sector. They are investing in the institutional architecture of a healthcare system that does not yet fully exist, but is being built now.
About Author: Rakshith Rangarajan, Fund Manager, Inviga is a seasoned finance professional with over 16 years of expertise spanning healthcare finance, corporate banking, and investment management.